The Clorox Company

NYSE:CLX Lagerbericht

Marktkapitalisierung: US$11.0b

Clorox Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Clorox wird ein jährliches Gewinn- und Umsatzwachstum von 7.8% bzw. 5.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 9.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 230.6% betragen.

Wichtige Informationen

7.8%

Wachstumsrate der Gewinne

9.90%

EPS-Wachstumsrate

Household Products Gewinnwachstum4.9%
Wachstumsrate der Einnahmen5.5%
Zukünftige Eigenkapitalrendite230.60%
Analystenabdeckung

Good

Zuletzt aktualisiert22 Jun 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Analyseartikel • Aug 02

Earnings Beat: The Clorox Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Shareholders might have noticed that The Clorox Company ( NYSE:CLX ) filed its yearly result this time last week. The...

Recent updates

Analyseartikel • Jun 16

Clorox (CLX) Stock Could Be 44% Below Fair Value Despite Recent Bounce

Clorox (CLX) stock has been drawing attention after recent performance figures showed mixed returns across different timeframes, prompting investors to reassess how the company’s current valuation lines up with its fundamentals and longer term track record. See our latest analysis for Clorox. At a share price of US$95.98, Clorox has seen its 30 day share price return rise 6.11%, while the 90 day share price return fell 13.84% and the 1 year total shareholder return declined 19.06%. This...
Narrativ-Update • Jun 13

CLX: GOJO Integration And Healthcare Expansion Will Shape Future Portfolio Multiple

Narrative Update The analyst price target for Clorox is updated lower from $115.47 to $105.29, reflecting a series of Street revisions as analysts factor in a slightly higher discount rate, modestly adjusted revenue growth and profit margin assumptions, and a lower future P/E multiple. Analyst Commentary Recent research on Clorox reflects a broad reset in expectations, with multiple firms trimming price targets and at least one downgrade from JPMorgan.
Seeking Alpha • Jun 07

The Reasons Why I Believe A Buy Rating Is Not Justified For Clorox (Rating Upgrade)

Summary Clorox managed to keep its sales flat YoY and improve its EPS slightly, despite contracting gross margins, due to elevated energy prices. Based on a dividend discount model, assuming 2% growth in perpetuity and a 7.7% required rate of return, the upside from the current price levels seems to be limited. For these reasons, I upgrade CLX to hold. Read the full article on Seeking Alpha
Narrativ-Update • May 30

CLX: Execution Risks And Leadership Transition Will Constrain Future Earnings Power

Clorox's analyst fair value estimate has been revised down from $94.00 to $83.00 as analysts factor in updated assumptions around discount rates, margins, and future P/E, in light of a broad wave of recent price target cuts across the Street. Analyst Commentary Recent Street research has tilted clearly cautious on Clorox, with a series of price target cuts and at least one downgrade from JPMorgan.
Narrativ-Update • May 14

CLX: GOJO Integration And Need Based Focus Will Support Long Term Earnings

Analysts have trimmed the blended fair value estimate for Clorox to about $144 from roughly $155, as a series of firms cut price targets, citing refreshed views on growth, margins, and future P/E multiples following recent research updates. Analyst Commentary Recent research has been dominated by cuts to fair value estimates and price targets, yet there are still some constructive signals in the commentary that matter if you are focused on Clorox's long term setup rather than just near term P/E compression.
Narrativ-Update • Apr 29

CLX: GOJO Integration And Need Based Portfolio Focus Will Shape Future Multiple

Analysts have trimmed their average price target on Clorox by about $4 to reflect revised assumptions around long term revenue growth, profit margins, and future P/E multiples after a recent wave of target cuts and a downgrade from several major firms. Analyst Commentary The recent research flow on Clorox shows a clear shift toward more cautious price targets, even as some firms earlier in the year had raised their estimates following company updates and sector moves.
Narrativ-Update • Apr 15

CLX: Execution Risks On Growth Plans Will Restrain Future Earnings Power

Clorox's updated analyst price target holds at $94.00, with recent Street research showing a series of both increases and cuts as analysts factor in revised assumptions for revenue growth, profit margins, and future P/E expectations. Analyst Commentary Recent Street research around Clorox has shifted toward more cautious pricing, with several bearish analysts trimming their targets after reassessing revenue, margin, and P/E assumptions.
Narrativ-Update • Mar 31

CLX: Mixed Organic Trends And GOJO Integration Will Shape Balanced Future Earnings Power

Analysts have trimmed Clorox's average price target by low double digit dollar amounts to around $94. This reflects mixed revisions across firms as they weigh softer volume expectations in consumer staples against company specific initiatives such as the GOJO acquisition and an increased focus on need based product innovation.
Narrativ-Update • Mar 17

CLX: Need Based Product Innovation And GOJO Integration Will Support Earnings Outlook

Analysts have inched their average price targets on Clorox higher, with multiple firms lifting targets into the $120s as they factor in Clorox's plans for need based product innovation and expected benefits from the GOJO acquisition, even as some caution remains around mixed organic sales trends and broader staples sector headwinds. Analyst Commentary Recent research on Clorox reflects a split view, with several bullish analysts lifting price targets into the low to mid US$120s while a few high profile firms remain cautious with targets closer to US$90 to US$110.
Narrativ-Update • Mar 03

CLX: Mixed Organic Trends And GOJO Integration Will Restrain Future Earnings Power

Analysts have nudged their average price target on Clorox higher by low single digits into the $120 range, citing refreshed sector targets, mixed but stable organic sales trends, and potential B2B upside from the GOJO acquisition. Analyst Commentary Recent research on Clorox has been mixed, with several firms lifting price targets into the low to mid $120s while keeping neutral or equal weight ratings.
Narrativ-Update • Feb 17

CLX: Lingering Distribution Issues Will Cap Earnings Power And Future P/E

The analyst price target for Clorox has shifted around recent revisions, with multiple firms raising or lowering their dollar price objectives as analysts weigh updated views on long term revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research on Clorox shows a split tape, with several firms lifting their price targets while others are trimming expectations or keeping a more cautious stance.
Narrativ-Update • Feb 03

CLX: Slower Distribution Recovery Will Restrain Earnings Power And Future Multiple

Analysts have reset their fair value estimate for Clorox to $94 from $115. This reflects updated assumptions for discount rates, modest revenue growth, slightly lower profit margins, and a reduced future P/E multiple, in line with recent mixed price target moves across the Street.
Narrativ-Update • Jan 20

CLX: ERP Normalization And Volume Recovery Concerns Will Shape Multiple Re Rating

Narrative Update The updated analyst price target for Clorox has shifted slightly lower to reflect a fair value move from about $122.41 to $119.76. Analysts are factoring in recent target cuts tied to softer guidance, slower expected volume recovery, and modestly lower revenue growth, profit margin, and future P/E assumptions, partially offset by at least one small upward revision.
Narrativ-Update • Jan 05

CLX: ERP Normalization And EPS Recovery Will Support Multiple Re Rating

Analysts have trimmed their price targets on Clorox, nudging our fair value estimate down by about $2 to $122.41 as they factor in softer Q1 results, a lower-end full-year EPS guide, and slightly more conservative assumptions for growth, margins, and future P/E. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q1 results and the full year EPS guide, while soft, were described as not as bad as feared, which they view as supportive of current valuation levels after the recent P/E reset.
Narrativ-Update • Dec 20

CLX: Margin Recovery And ERP Progress Will Support Earnings Outlook

Clorox's analyst price target has been reduced by about $5 to reflect softer near term results and guidance, with analysts citing muted growth expectations, operating deleverage from recent disruptions, and a more cautious outlook on topline and earnings across consumer staples. Analyst Commentary Bullish analysts acknowledge that Clorox's recent results and guidance were soft, but stress that the outcome was not as negative as many investors had anticipated.
Narrativ-Update • Dec 05

CLX: ERP Normalization And Cost Controls Will Drive Earnings Recovery

Analysts have trimmed their price targets on Clorox, collectively nudging our fair value view slightly lower, toward the Street’s new mid range around $117 to $125 per share, as they factor in softer near term results, muted growth expectations, and operating deleverage tied to service disruptions and cautious FY26 and FY27 outlooks. Analyst Commentary Analysts broadly view the latest quarter as soft but not thesis breaking, with valuation resets clustering around the low to mid $120s and embedding more modest growth and profitability assumptions.
Narrativ-Update • Nov 21

CLX: Share Buybacks And Cost Controls Will Support Recovery Into Fiscal 2026

Analysts have reduced their average price target for Clorox by a modest amount, from approximately $124.76 to $124.59. This adjustment is due to softer recent results and tempered growth expectations reflected in the latest earnings guidance and sector trends.
Analyseartikel • Nov 12

Here's Why Shareholders May Want To Be Cautious With Increasing The Clorox Company's (NYSE:CLX) CEO Pay Packet

Key Insights Clorox will host its Annual General Meeting on 19th of November Total pay for CEO Linda Rendle includes...
Analyseartikel • Nov 10

Clorox (NYSE:CLX) Strong Profits May Be Masking Some Underlying Issues

The market shrugged off The Clorox Company's ( NYSE:CLX ) solid earnings report. We did some digging and believe...
Narrativ-Update • Nov 06

CLX: Share Buybacks And Cost Controls Will Drive Resilience Into Fiscal 2026

Clorox's fair value price target has been lowered by analysts from $129.88 to $124.76, a change that reflects softer recent financial results and modest growth expectations, which are tempered by ongoing operational challenges. Analyst Commentary Recent analyst updates for Clorox reflect a mixed outlook, with both optimistic and cautious perspectives emerging in response to the company's latest financial results and ongoing challenges.
Narrativ-Update • Oct 23

Analysts Lower Clorox Price Target Amid Service Disruptions and Muted Profit Outlook

Clorox's analyst price target was reduced from approximately $131.24 to $129.88, as analysts cite ongoing service disruptions, slowing sales growth, and a muted profit outlook as key factors for the adjustment. Analyst Commentary Recent research updates indicate that analysts remain cautious on Clorox shares, reflecting ongoing challenges and a muted growth outlook.
Narrativ-Update • Oct 09

Modern ERP And Digital Marketing Will Unlock Lasting Opportunities

Clorox’s analyst price target has been lowered by approximately $2.35 per share. Analysts cite weaker revenue growth projections and ongoing operational challenges for the company.
Narrativ-Update • Aug 27

Modern ERP And Digital Marketing Will Unlock Lasting Opportunities

Clorox’s consensus price target was revised down to $135.06 as soft consumption data, ERP-related volatility, and weak guidance have undermined near-term sales and earnings visibility. Analyst Commentary Recent soft consumption data signals weakened demand, prompting concern over short-term sales trends.
Analyseartikel • Aug 04

Clorox (NYSE:CLX) Has Announced That It Will Be Increasing Its Dividend To $1.24

The Clorox Company ( NYSE:CLX ) will increase its dividend on the 29th of August to $1.24, which is 1.6% higher than...
Analyseartikel • Aug 02

Earnings Beat: The Clorox Company Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Shareholders might have noticed that The Clorox Company ( NYSE:CLX ) filed its yearly result this time last week. The...
Analyseartikel • Jul 16

Returns On Capital At Clorox (NYSE:CLX) Have Stalled

If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Seeking Alpha • Mar 29

Clorox: Reviving From Cyberattack; Initiate With 'Buy'

Summary I am initiating a 'Buy' rating for Clorox with a fair value of $153 per share, driven by strong brand equity and IT modernization efforts. Clorox's ERP upgrade and IT investments are expected to drive future growth, despite near-term costs and recent cyberattack impacts. Clorox anticipates 3%-5% organic revenue growth and 13%-19% adjusted EPS growth in FY25, supported by new ERP system rollout and cost management. Key risks include Walmart's pricing power, potential consumer shift to private labels, and tariff exposure, though mitigated by supply chain adjustments. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

Clorox: A Wonderful Business I Would Like To Own At A Lower Price

Summary Clorox is a wonderful business that sells everyday products across the world. It has many well-loved brands that customers love. The company has bounced back from the cyberattack it suffered in 2023, and has regained lost market share and improved margins. Wallstreet analysts across the board have upgraded their earnings expectations for CLX. However, there are real concerns facing it, and I do not think that investing in CLX at the current price offers me a favorable risk-reward scenario. Read the full article on Seeking Alpha
Seeking Alpha • Nov 26

The Clorox Company: Hold, Trading Above Fair Value Despite Positive Signals

Summary I rate The Clorox Company a hold due to its volatile financial performance and current stock trading above fair value. Despite revenue fluctuations, Clorox has strong brand recognition and promising growth potential, with 80% of sales from top-ranked products. The company's resilience is evident through consistent dividends, high ROE, ROCE, and positive EVA, indicating shareholder value creation. Clorox's recovery is marked by significant YoY growth in revenue, net income, and operational efficiency, showcasing potential for future growth. Read the full article on Seeking Alpha

Gewinn- und Umsatzwachstumsprognosen

NYSE:CLX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
6/30/20287,7838148141,25910
6/30/20277,5787728301,18114
6/30/20266,68161271189613
3/31/20266,760756380576N/A
12/31/20256,758755778984N/A
9/30/20256,771791636853N/A
6/30/20257,104810761981N/A
3/31/20257,0196948011,027N/A
12/31/20247,165457695923N/A
9/30/20247,469357669896N/A
6/30/20247,093280483695N/A
3/31/20247,209240570785N/A
12/31/20237,31080728944N/A
9/30/20237,035867941,000N/A
6/30/20237,3891499301,158N/A
3/31/20237,171748401,063N/A
12/31/20227,065435721951N/A
9/30/20227,041405678923N/A
6/30/20227,107462535786N/A
3/31/20227,108458563834N/A
12/31/20217,080247580869N/A
9/30/20217,231437620934N/A
6/30/20217,3417109451,276N/A
3/31/20217,5229231,3051,633N/A
12/31/20207,5241,2251,3831,677N/A
9/30/20207,1311,1511,3891,658N/A
6/30/20206,7219391,2921,546N/A
3/31/20206,3658709661,195N/A
12/31/20196,133816N/A1,041N/A
9/30/20196,157813N/A1,004N/A
6/30/20196,214820N/A992N/A
3/31/20196,278796N/A1,003N/A
12/31/20186,244790N/A1,101N/A
9/30/20186,187841N/A975N/A
6/30/20186,124823N/A976N/A
3/31/20186,080808N/A962N/A
12/31/20176,040799N/A922N/A
9/30/20176,030716N/A958N/A
6/30/20175,973703N/A865N/A
3/31/20175,926666N/A813N/A
12/31/20165,875653N/A863N/A
9/30/20165,814654N/A801N/A
6/30/20165,761648N/A778N/A
3/31/20165,718672N/A826N/A
12/31/20155,693657N/A782N/A
9/30/20155,693634N/A778N/A
6/30/20155,655606N/A874N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: CLXDas prognostizierte Gewinnwachstum (7.8% pro Jahr) liegt über der Sparquote (3.5%).

Ertrag vs. Markt: CLXDie Erträge des Unternehmens (7.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (18.9% pro Jahr).

Hohe Wachstumserträge: CLXDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: CLXDie Einnahmen des Unternehmens (5.5% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt US (13% pro Jahr).

Hohe Wachstumseinnahmen: CLXDie Einnahmen des Unternehmens (5.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: CLXDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich sehr hoch sein (230.6%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/06/23 03:25
Aktienkurs zum Tagesende2026/06/23 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/06/30

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

The Clorox Company wird von 31 Analysten beobachtet. 14 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
John StaszakArgus Research Company
Lauren LiebermanBarclays
Constance ManeatyBMO Capital Markets Equity Research